Invitation to presentation of Orexo´s Q3 2023 Interim Report

Uppsala, Sweden – October 26, 2023 – As previously communicated Orexo will announce the Interim Report for the third quarter of 2023 on November 2 at 8 am CET. The same day at 2 pm, analysts, investors, and media are invited to attend a presentation where Nikolaj Sørensen, CEO, and Fredrik Järrsten, CFO, will present the latest development and host a Q&A.

To attend via teleconference where you can ask questions verbally use this link:  https://conference.financialhearings.com/teleconference/?id=2001503
When registered you will be provided phone numbers and a conference ID to access the conference.

To attend via webcast:
https://ir.financialhearings.com/orexo-q3-2023

Prior to the event the presentation material will be available on the website under Investors/Reports, Presentations.

For further information, please contact:
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
Email: ir@orexo.com

About Orexo
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2022 amounted to SEK 624 million and the number of employees was 126. Orexo is listed on the Nasdaq Stockholm Main Market (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on X (former Twitter), LinkedIn and YouTube.